PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Active, not recruiting · NCT03299309 · Registry updated 2026-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, malignant glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-06-18 | NCT03299309 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Annias Immunotherapeutics, Inc. | 1 |
| Daniel Landi | 1 |
| Pediatric Brain Tumor Foundation | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University Medical Center | Durham | United States | 505 |